HCHéloïse Cardinal

Héloïse Cardinal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Héloïse Cardinal has a total of 207 co-authors. Here are the top co-authors by number of shared publications:

  • Lynne Sénécal

    Department of Medicine, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada

    4 shared publications
  • Marie-Josée Hébert

    Research Centre, Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, QC, Canada

    4 shared publications
  • Ruth Sapir-Pichhadze

    Centre for Outcomes Research and Evaluation (CORE) Research Institute of McGill University Health Centre Montréal Quebec Canada

    4 shared publications
  • Bethany J. Foster

    Research Institute of the McGill University Health Centre, Montréal, Québec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada; Department of Pediatrics, Division of Nephrology, McGill University Faculty of Medicine, Montréal, Québec, Canada

    3 shared publications
  • Julie Turgeon

    Research Center, Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, QC, Canada

    3 shared publications
  • Marie-Josée Hébert

    Centre de recherche, Centre hospitalier de l’Université de Montréal (CRCHUM), Montreal, Quebec, Canada

    3 shared publications

Latest Publications

  • Open Access

    A novel machine learning approach generates personalized estimates of graft and patient survival to better inform older kidney transplant candidates

    by Pierre-Luc Boivin, Jonathan Jalbert, Lévis Thériault, Yue Qi, Anastasiya Olek-Basanets, Héloise Cardinal

    Introduction: An information most relevant to patients when deciding to accept a kidney offer is an estimate of its potential longevity. Using a novel machine learning approach, our aim was to develop a model that can output personalized curves estimating kidney graft and patient longevity to support clinical decision-making. Methods: We performed a retrospective cohort study in recipients of a first deceased donor kidney transplant aged ≥60 years between 2000 and 2020, using the United Network for Organ Sharing dataset. Outcomes were overall graft survival and patient survival. Independent variables included the Kidney Donor Risk Index (KDRI) and recipient-related variables. Random survival forest models were trained on 70% and validated on 30% of the dataset. Results: The study cohort included 57, 280 patients, amongst whom 27, 244 (48%) experienced graft loss, while 25, 210 (44%) died during a median follow-up of 4.3 years. The most important variables in tree development for graft survival were recipient age, recipient diabetes, KDRI, recipient ethnicity, and time on dialysis. For patient survival, these variables were recipient age, recipient diabetes, time on dialysis, recipient cause of chronic kidney disease, and recipient HCV status. The difference in expected graft survival between low and high KDRI kidneys decreased when recipient characteristics, in particular age, were accounted for. KDRI had a negligible impact on mortality. Discussion: While implementation studies are needed, the individualized curves provided by our novel machine learning approach have the potential to support shared decision-making to a greater extent than the KDRI alone.

  • Open Access

    Endothelial extracellular vesicle miR-423-5p regulates microvascular homeostasis and renal function after ischemia-reperfusion injury

    by Francis Migneault, Hyunyun Kim, Alice Doreille, Shanshan Lan, Alexis Gendron, Marie-Hélène Normand, Annie Karakeussian Rimbaud, Martin Dupont, Isabelle Bourdeau, Éric Bonneil, et al.

    Microvascular rarefaction substantially contributes to renal dysfunction following ischemia-reperfusion injury (IRI). We characterized the microRNA signature of extracellular vesicles (EVs) released during endothelial apoptosis to identify biomarkers and regulators of microvascular rarefaction and renal dysfunction. Using in vitro models and RNA-Seq, we found miR-423-5p, let-7b-5p, and let-7c-5p enriched in small EVs from apoptotic endothelial cells. In mouse models of renal IRI and a cohort of 51 patients who have undergone renal transplant with delayed graft function, serum miR-423-5p correlated with circulating EVs, while let-7b-5p and let-7c-5p were also present in free form. Early acute kidney injury saw increased serum miR-423-5p levels linked to small EVs with endothelial markers. Over time, higher serum miR-423-5p levels were associated with large EVs and correlated with greater renal microvascular density and reduced fibrosis. Microvascular density and fibrosis predicted renal function 3 years after transplantation. We explored miR-423-5p’s role in renal homeostasis, finding that its injection during renal IRI preserved microvascular density and inhibited fibrosis. Endothelial cells transfected with miR-423-5p showed enhanced resistance to apoptosis, increased migration, and angiogenesis. Localized miR-423-5p injection in hindlimb ischemia model accelerated revascularization. These findings position miR-423-5p as a predictor of renal microvascular rarefaction and fibrosis, highlighting potential strategies for preserving renal function.


  • Open Access

    Clinical Urinary Tract Infections in Kidney Transplant Recipients With Initially Asymptomatic Bacteriuria: A Single-Center Retrospective Cohort Study

    by Samar Medani, Marc Dorais, Aurélie Poulin, Alexandre Tavares-Brum, Habib Mawad, Alain Duclos, Azemi Barama, Héloïse Cardinal


  • Open Access

    Exposure to renin-angiotensin system inhibitors before kidney transplantation is associated with a decreased risk of delayed graft function

    by Gan Zhen Liang, Marc Dorais, Suzon Collette, Lynne Sénécal, Majda Belkaid, Julie Turgeon, Héloïse Cardinal

    Introduction: Animal models suggest a protective role of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-II receptor blockers (ARBs) in reducing renal and cardiac ischemia-reperfusion injury. Our aim was to determine the association between pre-transplant ACEi/ARBs use and the occurrence of delayed graft function (DGF) in patients who received a kidney transplantation from a deceased donor.Methods: Consecutive recipients between 2008 and 2021 in 2 Canadian university-affiliated centers were included in this retrospective cohort study. The main outcome was the occurrence of DGF and the exposure was use of ACEi or ARBs at the time of admission for transplantation. Mixed models were fit.Results: A total of 897 patients were included, of which 160 (18%) experienced DGF. At admission, 337 (38%) patients were exposed to ACEi/ARBs. In the multivariable analysis, pre-transplant ACEi/ARBs use was associated with a reduced risk of DGF (odds ratio: 0.60, 95% confidence interval: 0.40, 0.92). Other factors associated with DGF were recipient obesity, donor type, ethnicity, age, hypertension, and total ischemia time.Discussion: Pre-transplant use of ACEi/ARBs is associated with a lower risk of DGF in early postoperative period, which may be due to a protective effect of these agents on renal ischemia-reperfusion injury.


  • Open Access

    A Canado-European external validation of the Kidney Transplant Failure Score

    by Arthur Chatton, Kevin Assob Feugo, Émilie Pilote, Héloïse Cardinal, Robert W. Platt, Mireille E. Schnitzer

    In kidney transplantation, obtaining early information about the risk of graft failure helps physicians and patients anticipate a potential return to dialysis or retransplantation. Clinical prediction models are commonly used to obtain such risk estimation, but their performance needs to be continuously evaluated in various contexts. We propose an external validation study of the Kidney Transplant Failure Score in a pooled sample of 3,144 patients transplanted between 2010 and 2015 in France, Belgium, Norway and Canada. This score is used at the first transplantation anniversary to predict the probability of graft failure over the following seven years. The target population was defined as adult recipients of a kidney from a neurologically deceased donor without graft failure in the first year post-transplantation. Graft failure was defined as a return to dialysis. Around 10% of patients returned to dialysis, and 12.6% died during the seven-year follow-up. The KTFS authors fitted a Cox model and then adjusted its coefficients to maximize the discrimination, yielding the KTFS final version. We evaluated the performance of the initial and final versions of the KTFS, as well as the performance of another model we developed to consider death as a competing event. All KTFS versions yielded similarly good discrimination (area under the time-dependant receiver operating curve around from 0.79 [0.76-0.82] to 0.80 [0.77-0.84]), while the discrimination-optimized one presented important miscalibration. Clinical utility, assessed through net benefit, was also the lowest for the discrimination-optimized version. Our results warn against using the current KTFS version and recommend using either the initial coefficients or the competing risk-based ones instead. Lay summary: French nephrologists have used the Kidney Transplant Failure Score (KTFS) for nearly fifteen years to predict kidney graft failure eight years after the transplantation. Because predictive performance decreases over time, we first verified that the score could still predict correctly in France and also in other countries. Then, we compared the different KTFS formulas to find that the one currently used is suboptimal and should be avoided. Our findings show that the KTFS is still a reliable source of information for both kidney recipients and nephrologists when using its first version.

  • Open Access

    Differences in excess mortality by recipient sex after heart transplant: An individual patient data meta-analysis

    by Amanda J. Vinson, Xun Zhang, Mourad Dahhou, Caner Süsal, Bernd Döhler, Anette Melk, Ruth Sapir-Pichhadze, Heloise Cardinal, Germaine Wong, Anna Francis, et al.


  • Open Access

    NephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study

    by Matthieu-P Schapranow, Mozhgan Bayat, Aadil Rasheed, Marcel Naik, Verena Graf, Danilo Schmidt, Klemens Budde, Héloïse Cardinal, Ruth Sapir-Pichhadze, Franz Fenninger, et al.

    Background: Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis of complex data in a wide range of daily-life use cases. We aim to explore the benefits of applying AI to a specific use case in transplant nephrology: risk prediction for severe posttransplant events. For the first time, we combine multinational real-world transplant data, which require specific legal and technical protection measures. Objective: The German-Canadian NephroCAGE consortium aims to develop and evaluate specific processes, software tools, and methods to (1) combine transplant data of more than 8000 cases over the past decades from leading transplant centers in Germany and Canada, (2) implement specific measures to protect sensitive transplant data, and (3) use multinational data as a foundation for developing high-quality prognostic AI models. Methods: To protect sensitive transplant data addressing the first and second objectives, we aim to implement a decentralized NephroCAGE federated learning infrastructure upon a private blockchain. Our NephroCAGE federated learning infrastructure enables a switch of paradigms: instead of pooling sensitive data into a central database for analysis, it enables the transfer of clinical prediction models (CPMs) to clinical sites for local data analyses. Thus, sensitive transplant data reside protected in their original sites while the comparable small algorithms are exchanged instead. For our third objective, we will compare the performance of selected AI algorithms, for example, random forest and extreme gradient boosting, as foundation for CPMs to predict severe short- and long-term posttransplant risks, for example, graft failure or mortality. The CPMs will be trained on donor and recipient data from retrospective cohorts of kidney transplant patients. Results: We have received initial funding for NephroCAGE in February 2021. All clinical partners have applied for and received ethics approval as of 2022. The process of exploration of clinical transplant database for variable extraction has started at all the centers in 2022. In total, 8120 patient records have been retrieved as of August 2023. The development and validation of CPMs is ongoing as of 2023. Conclusions: For the first time, we will (1) combine kidney transplant data from nephrology centers in Germany and Canada, (2) implement federated learning as a foundation to use such real-world transplant data as a basis for the training of CPMs in a privacy-preserving way, and (3) develop a learning software system to investigate population specifics, for example, to understand population heterogeneity, treatment specificities, and individual impact on selected posttransplant outcomes. International Registered Report Identifier (IRRID): DERR1-10.2196/48892


  • Open Access

    NephroCAGE—German-Canadian Consortium on AI for Improved Kidney Transplantation Outcome: Protocol for an Algorithm Development and Validation Study (Preprint)

    by Matthieu-P Schapranow, Mozhgan Bayat, Aadil Rasheed, Marcel Naik, Verena Graf, Danilo Schmidt, Klemens Budde, Héloïse Cardinal, Ruth Sapir-Pichhadze, Franz Fenninger, et al.

    BACKGROUND Recent advances in hardware and software enabled the use of artificial intelligence (AI) algorithms for analysis of complex data in a wide range of daily-life use cases. We aim to explore the benefits of applying AI to a specific use case in transplant nephrology: risk prediction for severe posttransplant events. For the first time, we combine multinational real-world transplant data, which require specific legal and technical protection measures. OBJECTIVE The German-Canadian NephroCAGE consortium aims to develop and evaluate specific processes, software tools, and methods to (1) combine transplant data of more than 8000 cases over the past decades from leading transplant centers in Germany and Canada, (2) implement specific measures to protect sensitive transplant data, and (3) use multinational data as a foundation for developing high-quality prognostic AI models. METHODS To protect sensitive transplant data addressing the first and second objectives, we aim to implement a decentralized NephroCAGE federated learning infrastructure upon a private blockchain. Our NephroCAGE federated learning infrastructure enables a switch of paradigms: instead of pooling sensitive data into a central database for analysis, it enables the transfer of clinical prediction models (CPMs) to clinical sites for local data analyses. Thus, sensitive transplant data reside protected in their original sites while the comparable small algorithms are exchanged instead. For our third objective, we will compare the performance of selected AI algorithms, for example, random forest and extreme gradient boosting, as foundation for CPMs to predict severe short- and long-term posttransplant risks, for example, graft failure or mortality. The CPMs will be trained on donor and recipient data from retrospective cohorts of kidney transplant patients. RESULTS We have received initial funding for NephroCAGE in February 2021. All clinical partners have applied for and received ethics approval as of 2022. The process of exploration of clinical transplant database for variable extraction has started at all the centers in 2022. In total, 8120 patient records have been retrieved as of August 2023. The development and validation of CPMs is ongoing as of 2023. CONCLUSIONS For the first time, we will (1) combine kidney transplant data from nephrology centers in Germany and Canada, (2) implement federated learning as a foundation to use such real-world transplant data as a basis for the training of CPMs in a privacy-preserving way, and (3) develop a learning software system to investigate population specifics, for example, to understand population heterogeneity, treatment specificities, and individual impact on selected posttransplant outcomes. CLINICALTRIAL INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48892

  • Open Access

    Hypothermic Perfusion Modifies the Association Between Anti-LG3 Antibodies and Delayed Graft Function in Kidney Recipients

    by Habib Mawad, Louis Pinard, Samar Medani, Miguel Chagnon, Julie Boucquemont, Julie Turgeon, Mélanie Dieudé, Katia Hamelin, Annie Karakeussian Rimbaud, Ali Belayachi, et al.

    We previously reported associations between autoantibodies to the LG3 fragment of perlecan, anti-LG3, and a higher risk of delayed graft function (DGF) in kidney transplant recipients. Here, we aimed to determine whether some factors that modulate ischemia-reperfusion injury (IRI) can modify this association. We performed a retrospective cohort study in kidney transplant recipients in 2 university-affiliated centers. In 687 patients, we show that high pre-transplant anti-LG3 are associated with DGF when the kidney is transported on ice (odds ratio (OR): 1.75, 95% confidence interval 1.02–3.00), but not when placed on hypothermic perfusion pump (OR: 0.78, 95% CI 0.43–1.37). In patients with DGF, high pre-transplant anti-LG3 are associated with a higher risk of graft failure (subdistribution hazard ratio (SHR): 4.07, 95% CI: 1.80, 9.22), while this was not the case in patients with immediate graft function (SHR: 0.50, 95% CI 0.19, 1.29). High anti-LG3 levels are associated with a higher risk of DGF in kidneys exposed to cold storage, but not when hypothermic pump perfusion is used. High anti-LG3 are also associated with a higher risk of graft failure in patients who experience DGF, a clinical manifestation of severe IRI.


  • Open Access

    Double Pretransplant Positivity for Autoantibodies to LG3 and Angiotensin II Type 1 Receptor Is Associated With Alloimmune Vascular Injury in Kidney Transplant Recipients

    by Robert Md Carroll, Julie Turgeon, Sue Bsc (Hons) Deayton, Tim Bsc Emery, Fiona Certificate Bilogrevic, Sadia Jahan, Annie Karakeussian Bsc Rimbaud, Barbara Georges, Alexandre Bsc Tavares-Brum, Marie-Josée Hébert, et al.

    Export Background. Both angiotensin II receptor autoantibodies (ATRabs) and autoantibodies to LG3 have been linked to kidney graft rejection with alloimmune vascular injury (AVI). We aimed to examine whether positivity for both anti-LG3 and ATRabs is associated with rejection with AVI in kidney transplant recipients. Methods. We performed a retrospective cohort study including consecutive kidney transplant recipients between 2013 and 2017 at a single center. The primary outcome was acute rejection with AVI (Banff grade 2 or 3 T-cell-mediated rejection and/or antibody-mediated rejection) in the first 3 mo posttransplant. The secondary outcome was death-censored allograft loss. The independent variables, anti-LG3 and ATRab, were measured pretransplant. Results. Among the 328 study participants, 68 experienced acute rejection with AVI and 23 experienced graft loss over a median follow-up of 4.5 y. In a multivariable model, double pretransplant positivity for anti-LG3/ATRab was associated with acute rejection with AVI (odds ratio: 2.73, 95% confidence interval: 1.06-7.05). We did not observe an association between double positivity for anti-LG3/ATRab and death-censored graft loss. Conclusions. Double positivity for anti-LG3/ATRabs pretransplant is associated with a higher risk of acute rejection with AVI. Whether therapies that remove antibodies could decrease that risk remains to be studied. Supplemental Visual Abtract: https://links.lww.com/TXD/A494 .